UK markets closed


LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.0931+0.1731 (+18.82%)
At close: 04:54PM BST


33 43 av. Georges Pompidou Bât. D2
Balma 31130
33 5 62 24 97 06

Full-time employees

Key executives

NameTitlePayExercisedYear born
Sir Cyrille Tupin CPACEO, GM & Director289.28kN/A1977
Prof. Christian Chavy MBAIndependent Director28kN/A1950
Mr. Emmanuel De FougerouxAdministrative & Financial DirectorN/AN/AN/A
Ms. Constance Keyserling Peyrottes M.S.Vice President of Clinical, Regulatory Development & OperationsN/AN/A1961
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

Corporate governance

ABIONYX Pharma SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.